IL269286B2 - Subcutaneous administration of a p2y12 receptor antagonist - Google Patents
Subcutaneous administration of a p2y12 receptor antagonistInfo
- Publication number
- IL269286B2 IL269286B2 IL269286A IL26928619A IL269286B2 IL 269286 B2 IL269286 B2 IL 269286B2 IL 269286 A IL269286 A IL 269286A IL 26928619 A IL26928619 A IL 26928619A IL 269286 B2 IL269286 B2 IL 269286B2
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonist
- administered
- pharmaceutically acceptable
- acceptable salt
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017056175 | 2017-03-15 | ||
| PCT/EP2018/056372 WO2018167139A1 (en) | 2017-03-15 | 2018-03-14 | Subcutaneous administration of a p2y12 receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL269286A IL269286A (en) | 2019-11-28 |
| IL269286B1 IL269286B1 (en) | 2023-04-01 |
| IL269286B2 true IL269286B2 (en) | 2023-08-01 |
Family
ID=61899166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL269286A IL269286B2 (en) | 2017-03-15 | 2019-09-11 | Subcutaneous administration of a p2y12 receptor antagonist |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11179390B2 (enExample) |
| EP (1) | EP3595666A1 (enExample) |
| JP (2) | JP7580918B2 (enExample) |
| KR (1) | KR102510832B1 (enExample) |
| CN (1) | CN110381947A (enExample) |
| AU (1) | AU2018234056B2 (enExample) |
| BR (1) | BR112019014567A2 (enExample) |
| CL (1) | CL2019002318A1 (enExample) |
| EA (1) | EA201992123A1 (enExample) |
| IL (1) | IL269286B2 (enExample) |
| MA (1) | MA49887A (enExample) |
| MX (1) | MX393334B (enExample) |
| MY (1) | MY205605A (enExample) |
| PH (1) | PH12019502111A1 (enExample) |
| SG (1) | SG11201908128YA (enExample) |
| TW (1) | TWI765002B (enExample) |
| UA (1) | UA125531C2 (enExample) |
| WO (1) | WO2018167139A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109715639B (zh) | 2016-09-22 | 2022-04-19 | 爱杜西亚药品有限公司 | 结晶形式 |
| TWI905227B (zh) * | 2020-07-15 | 2025-11-21 | 新加坡商暉致亞太私人有限公司 | 包含p2y12受體拮抗劑的水性醫藥組合物 |
| CA3223733A1 (en) | 2021-07-13 | 2023-01-19 | Nicole Blumer | A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester |
| CN118871446A (zh) | 2022-03-14 | 2024-10-29 | 晖致亚太私人有限公司 | (r)-2-((叔丁氧基羰基)氨基)-3-(二乙氧基磷酰基)丙酸或其膦酸酯衍生物的合成方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870035A (en) | 1970-07-17 | 1975-03-11 | Survival Technology | Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms |
| US4004577A (en) | 1972-12-04 | 1977-01-25 | Survival Technology, Inc. | Method of treating heart attack patients prior to the establishment of qualified direct contact personal care |
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| US5078680A (en) | 1984-08-08 | 1992-01-07 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US4795433A (en) | 1985-05-20 | 1989-01-03 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US4658830A (en) | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
| GR861289B (en) | 1985-05-20 | 1986-09-16 | Survival Technology | Injection method and apparatus with electrical blood absorbing stimulation |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| CA2375920A1 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| CN1747732A (zh) | 2002-12-11 | 2006-03-15 | 舍林股份公司 | 作为血小板腺苷二磷酸受体拮抗剂的2－氨基羰基喹啉化合物 |
| WO2004092189A1 (en) | 2003-04-09 | 2004-10-28 | Wyeth | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| WO2005002574A1 (en) | 2003-06-24 | 2005-01-13 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| ES2421448T3 (es) | 2005-10-21 | 2013-09-02 | Actelion Pharmaceuticals Ltd | Derivados de piperazina como agentes contra la malaria |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CA2684644A1 (en) | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| US20090048216A1 (en) | 2007-05-02 | 2009-02-19 | Portola Pharmaceuticals, Inc. | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| RU2483072C2 (ru) | 2007-11-29 | 2013-05-27 | Актелион Фармасьютиклз Лтд | Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12 |
| EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| MX2011010200A (es) | 2009-04-08 | 2011-10-14 | Actelion Pharmaceuticals Ltd | 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp). |
| JP5536876B2 (ja) | 2009-04-22 | 2014-07-02 | アクテリオン ファーマシューティカルズ リミテッド | チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用 |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| EP2585161A1 (en) | 2010-06-23 | 2013-05-01 | Stefan Kralev | Medical device for self-administration of patients with acute coronary events |
| CN109715639B (zh) | 2016-09-22 | 2022-04-19 | 爱杜西亚药品有限公司 | 结晶形式 |
-
2018
- 2018-03-14 SG SG11201908128Y patent/SG11201908128YA/en unknown
- 2018-03-14 US US16/494,254 patent/US11179390B2/en active Active
- 2018-03-14 MY MYPI2019005278A patent/MY205605A/en unknown
- 2018-03-14 EP EP18715499.2A patent/EP3595666A1/en active Pending
- 2018-03-14 JP JP2019549420A patent/JP7580918B2/ja active Active
- 2018-03-14 MA MA049887A patent/MA49887A/fr unknown
- 2018-03-14 TW TW107108546A patent/TWI765002B/zh active
- 2018-03-14 KR KR1020197029753A patent/KR102510832B1/ko active Active
- 2018-03-14 MX MX2019009559A patent/MX393334B/es unknown
- 2018-03-14 UA UAA201910293A patent/UA125531C2/uk unknown
- 2018-03-14 AU AU2018234056A patent/AU2018234056B2/en active Active
- 2018-03-14 WO PCT/EP2018/056372 patent/WO2018167139A1/en not_active Ceased
- 2018-03-14 CN CN201880017104.XA patent/CN110381947A/zh active Pending
- 2018-03-14 BR BR112019014567-2A patent/BR112019014567A2/pt not_active Application Discontinuation
- 2018-03-14 EA EA201992123A patent/EA201992123A1/ru unknown
-
2019
- 2019-08-16 CL CL2019002318A patent/CL2019002318A1/es unknown
- 2019-09-11 IL IL269286A patent/IL269286B2/en unknown
- 2019-09-13 PH PH12019502111A patent/PH12019502111A1/en unknown
-
2023
- 2023-01-23 JP JP2023008155A patent/JP7902762B2/ja active Active
Non-Patent Citations (3)
| Title |
|---|
| BALDONI DANIELA ET AL,, A NEW REVERSIBLE AND POTENT P2Y12 RECEPTOR ANTAGONIST (ACT-246475): TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN A FIRST-IN-MAN TRIAL, 1 November 2014 (2014-11-01) * |
| EVA CAROFF ET AL,, 4-(( R )-2-{[6-(( S )-3-METHOXYPYRROLIDIN-1-YL)-2-PHENYLPYRIMIDINE-4-CARBONYL]AMINO}-3-PHOSPHONOPROPIONYL)PIPERAZINE-1-CARBOXYLIC ACID BUTYL ESTER (ACT-246475) AND ITS PRODRUG (ACT-281959), A NOVEL P2Y 12 RECEPTOR ANTAGONIST WITH A WIDER THERAPEUTIC , 10 December 2015 (2015-12-10) * |
| PEER TFELT-HANSEN,, PARENTERAL VS. ORAL SUMATRIPTAN AND NARATRIPTAN: PLASMA LEVELS AND EFFICACY IN MIGRAINE. A COMMENT, 23 January 2007 (2007-01-23) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019002318A1 (es) | 2020-01-10 |
| JP2020510043A (ja) | 2020-04-02 |
| US20200129510A1 (en) | 2020-04-30 |
| JP2023052576A (ja) | 2023-04-11 |
| MA49887A (fr) | 2020-06-24 |
| IL269286A (en) | 2019-11-28 |
| MX2019009559A (es) | 2019-10-15 |
| KR20190124297A (ko) | 2019-11-04 |
| WO2018167139A1 (en) | 2018-09-20 |
| JP2025060907A (ja) | 2025-04-10 |
| MX393334B (es) | 2025-03-24 |
| MY205605A (en) | 2024-10-29 |
| IL269286B1 (en) | 2023-04-01 |
| SG11201908128YA (en) | 2019-10-30 |
| UA125531C2 (uk) | 2022-04-13 |
| AU2018234056A1 (en) | 2019-10-31 |
| TW201840323A (zh) | 2018-11-16 |
| NZ757938A (en) | 2024-07-05 |
| EP3595666A1 (en) | 2020-01-22 |
| BR112019014567A2 (pt) | 2020-02-18 |
| JP7580918B2 (ja) | 2024-11-12 |
| AU2018234056B2 (en) | 2023-05-25 |
| TWI765002B (zh) | 2022-05-21 |
| PH12019502111A1 (en) | 2020-03-16 |
| CA3050831A1 (en) | 2018-09-20 |
| CN110381947A (zh) | 2019-10-25 |
| JP7902762B2 (ja) | 2026-08-10 |
| KR102510832B1 (ko) | 2023-03-15 |
| EA201992123A1 (ru) | 2020-02-25 |
| US11179390B2 (en) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023052576A (ja) | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 | |
| EP3380095B1 (en) | Compositions and methods for treating ischemic stroke | |
| KR20180032578A (ko) | 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도 | |
| EP4592294A1 (en) | Novel carbamate compound and use thereof | |
| KR20140022052A (ko) | 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도 | |
| ES2894801T3 (es) | Agente para prevenir y/o tratar la enfermedad de Alzheimer | |
| KR20110013352A (ko) | 심혈관 질환을 치료하기 위한 라놀라진의 용도 | |
| CA3050831C (en) | Subcutaneous administration of a p2y12 receptor antagonist | |
| KR20100038322A (ko) | 당뇨병 치료 방법 | |
| TWI905227B (zh) | 包含p2y12受體拮抗劑的水性醫藥組合物 | |
| JP2023082167A (ja) | 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物 | |
| EA042138B1 (ru) | Подкожное введение антагониста p2y12 рецептора | |
| Thakur¹ et al. | Review on chemistry and pharmacology of dabigatran a potent anticoagulant | |
| HK40094173A (en) | Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist | |
| HK40094173B (en) | Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist |